Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mirfenacin MR vs Vesicare & Betmiga in Healthy Volunteers
NCT05767632Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of solifenacin and mirabegron in overactive bladder (OAB), sponsored by Genuine Research Center. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) for Solifenacin, Area Under the Curve to 72 hours (AUC0->72) for Solifenacin and 3 more. Started May 2022; status: completed.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05767632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767632.